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Abstract 1 
Objective: To compare dietary intake and lifestyle behaviour in women with polycystic ovarian 2 
syndrome (PCOS) and healthy women. 3 
Methods: 160 healthy women (partner with male infertility) were recruited to a control group; 4 
168 women with PCOS (diagnosed on ultrasound) were recruited to a case study group for this 5 
cross-sectional comparative study. The case group was classified into three phenotypes based on 6 
presence or absence of menstrual disorder (M), hyperandrogenism (HA), and polycystic ovary 7 
according to sonography (PCO): HA+PCO (n=53), PCO+M (n=57) and M+HA+PCO (n=66). 8 
Dietary intake and lifestyle behaviour were measured using a food frequency questionnaire 9 
(FFQ) and a lifestyle questionnaire (LQ). 10 
Results: The mean energy (P<0.001) and fat intake (P<0.001) were greater in PCOS groups 11 
compared with the control group. The average energy and fat intake were greater in 12 
HA+M+PCO group after age and BMI adjustment compared with other phenotypes (P<0.001). 13 
In comparison with the control group, lifestyle scores were lower in the PCOS group in the fields 14 
of physical activity, weight and nutrition control after age and BMI adjustment (P<0.001). The 15 
average score of lifestyle in the fields of physical activity, weight and nutrition control, and 16 
psychological health was lower in the phenotype HA+M+PCO compared with other phenotypes 17 
(P<0.001). 18 
Conclusions: Limited energy and fat intake is strongly recommended in Iranian women with 19 
PCOS especially in phenotype HA+M+PCO. Consultation on improvement of psychological 20 
health and the importance of weight and nutrition control, and appropriate physical activity in 21 
patients especially in HA+M+PCO is advocated. 22 
Keywords: Lifestyle, polycystic ovarian syndrome, diet  23 
24 
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Introduction 25 
Polycystic ovarian syndrome (PCOS) is a common and complex endocrine disorder that affects 26 
women of reproductive age (1). Three phenotypes are recognized based on the presence or 27 
absence of symptoms using the Rotterdam criteria: oligo-ovulation (irregular menses) with 28 
polycystic ovary in sonography (M+PCO), hyperandrogenism with polycystic ovary in 29 
sonography (HA+PCO) and hyperandrogenism with oligo-ovulation (irregular menses) and 30 
polycystic ovary (M+PCO+HA) (2, 3). Although, PCOS can exist in the absence of obesity, 70 31 
percent of women with PCOS are obese (4).  32 
 33 
Obesity can intensify metabolic and fertility outcomes related to this syndrome. For this reason, 34 
the treatment of PCOS focuses mainly on weight loss if obesity is present because energy 35 
limitation is associated with improved metabolic status and energy intakes (5-7). However, the 36 
relationship between diet and PCOS is not yet well understood and there is limited information 37 
available in this field. It is reported that total energy intake and intake of micronutrients is similar 38 
in PCOS and control groups (Carmina et al.8) and that consumption of certain foods with high 39 
glycaemic index is greater in women with PCOS (Douglas et al.9). Extensive long-term studies 40 
have identified a significant relationship between diet and the risk of hypertension, type 2 41 
diabetes mellitus (T2DM), and cardiovascular disease in a healthy population (10-14). Most studies 42 
which assess the nutritional status of women with PCOS are flawed because they do not allow 43 
for the different clinical phenotypes in PCOS which result in significantly different clinical and 44 
metabolic parameters. Pikee et al. (15) have reported that women with the hyperandrogenism 45 
phenotype have a higher BMI and worse clinical and endocrine status (TG/HDL, LH/FSH, 46 
testosterone, LH) compared with other phenotypes. The only study which has investigated the 47 
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potential differences between phenotypes in PCOS and their dietary intake has reported that 48 
women with phenotype HA+M+PCO had more daily energy intake compared with healthy 49 
women (16).  50 
 51 
Dietary habits are rooted in the culture of communities, and since the relationship between 52 
dietary habits and the prevalence of some cardiovascular disease and T2DM is proven, it seems 53 
logical and imperative to compare dietary intake between women with different phenotypes of 54 
PCOS in different cultures. To deliver appropriate nutritional interventions in the case of obesity 55 
or increased risk factors related to diet, PCOS cardiovascular status is required. The purpose of 56 
the present study was to compare dietary intake and lifestyle factors in women with three 57 
different phenotypes of PCOS with a control group of healthy women. 58 
 59 
Methods  60 
Design and data collection 61 
The present study is a cross sectional study with a control and case group divided into three sub-62 
groups. The study was conducted at an acute hospital in Hormozgan Province, Iran. Women 63 
were recruited through the infertility clinic at a provincial hospital. The case group included 64 
women with PCOS.  The control group comprised healthy women who had been referred to this 65 
clinic because of male infertility.  66 
A simple sampling method was used. The sample size was calculated using the following 67 
formula (Douglas et al.9) with CI 95% as at least 145 women in each group. 68 
 
2
2
2
2
1
2
1
2
1













SSZZ
N

 69 
4 
 
μ1: 61.5; μ2: 69.2; S1:  21.1; S2: 25.0. 70 
The research team approached 362 women to explain the purpose of study; written consent was 71 
obtained from each participant who volunteered to participate and questionnaires were 72 
distributed and completed at the same clinic appointment. 34/362 women declined for unknown 73 
reasons. Inclusion criteria for all groups were: age 15-40 years, married, Iranian nationality, and 74 
absence of linguistic or cognitive problems, lack of underlying disease (diabetes, hypertension, 75 
diagnosed anaemia, or any other disease requiring a special diet). Additional inclusion criteria 76 
for the case group were women with PCOS based on two of the following three Rotterdam 77 
criteria: ultrasound scan of polycystic ovary (>12 follicles in both ovaries and ovarian volume 78 
>10 mm); clinical signs of hyperandrogenism: clinical score of hyperandrogenism >7 or obvious 79 
acne);  menstrual cycles of greater than 35 days or amenorrhea (absence of menstruation for 199 80 
days). And absence of congenital adrenal hyperplasia, thyroid dysfunction, hyperprolactinemia.  81 
The selected participants in the case group were classified into three phenotypes: HA+PCO, 82 
M+PCO, HA+M+PCO.  83 
 84 
Measures 85 
Menstrual history measured as the interval between two menses during the previous 12 months: 86 
<21 days, 21-34 days, 35-60 days, >199 days, variable. 87 
BMI: calculated as an individual’s weight in kilograms divided by height in metres2  88 
Body hair: based on the Ferriman-Gallway hirsutism scoring scale which measures nine 89 
androgen sensitive areas in the body. Each area is rated from zero to 4 based on the degree of 90 
terminal hair growth. A score of 7 or more indicated hirsutism (17). 91 
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Acne: a global acne grading system was used to measure acne. This scale includes six body areas 92 
of face, chest, and upper back based on the level of involvement, distribution, density, and 93 
pilosebaceous units. Each body area is rated from zero to four. The most severe lesion of each 94 
area determines the score of that area. The score of each area is multiplied by the factor score 95 
which is based on the involved area: forehead, left and right cheek, nose, chin, chest and upper 96 
back. The total acne score is obtained by multiplying the factor score by sum score of involved 97 
areas (18). 98 
Socio economic status: formal education of women was considered as an indicator of social 99 
status (19). 100 
Food frequency questionnaire: dietary intake was measured using a modified food frequency 101 
questionnaire (FFQ) based on Iranian dietary questionnaire which contains 168 items. The 102 
reliability and validity of the questionnaire are approved in Iran (20). FFQ included a list of foods 103 
with a standard size of a food. Subjects were asked to report the frequency of consumption of 104 
each food during the past month on a daily, weekly or monthly basis. The amount of nutritional 105 
items consumed was converted to grams using household scales. This dietary information was 106 
analyzed using the software Nutrition4 which calculated the amount of energy, macronutrients 107 
(carbohydrates, lipid, and protein) and micronutrients (at least 30 micronutrients) including fat 108 
soluble vitamins, water soluble vitamins and minerals (20, 21). 109 
 110 
Lifestyle questionnaire (LSQ) which compromises 70 items in 10 subscales including physical 111 
health (8 items), sports and fitness (7 items), weight management and nutrition (7 items), disease 112 
prevention (7 items), mental health (7 items), spiritual health (6 items), social health (7 items), 113 
avoidance of drugs, alcohol and opiates (6 items), accident prevention (8 items) and 114 
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environmental health (7 items). All items are graded on a four-point Likert scale scoring in range 115 
from 0 (=never) to 3 (=always). The higher the score, the better the lifestyle. Lali et al. (22) have 116 
confirmed the validity and reliability of this questionnaire for Iranian society.  117 
 118 
Ethical consideration 119 
The ethics committee of Hormozgan University of Medical Science approved the present study. 120 
After explaining the purpose of the study and securing the confidentiality of information, all 121 
subjects gave written consent. 122 
 123 
Statistical analysis 124 
The Mean ± SD and n (%) were used for quantitative and qualitative variables respectively. T 125 
test and ANOVA test were used for intergroup comparison of PCOS patients for quantitative 126 
variables and comparison of PCOS phenotypes respectively. BMI and age were adjusted by co-127 
variance analysis. Data were analyzed using Statistical Package for the Social Sciences 21.0 128 
(SPSS Inc., Chicago, IL, USA). Significance level of P<0.05 was accepted. 129 
 130 
Results 131 
Study population 132 
Table 1 shows the clinical and demographic information of all participants. There was no 133 
significant difference between the control and case study groups in terms of demographic and 134 
clinical characteristics except for menstrual cycle interval, hirsutism and acne scores (P>0.05). 135 
There were no significant differences between three PCOS phenotype groups in terms of 136 
demographic and clinical characteristics. 137 
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 138 
Dietary intake 139 
Table 2 shows the comparison of women with PCOS and the women in the control group based 140 
on their dietary intake. Energy and fat intake were greater in the PCOS group after adjustment 141 
for BMI and age compared with control group (P<0.01).  Table 3 shows dietary intake in the 142 
different phenotypes of PCOS. Energy intake and fat intake were significantly higher in 143 
phenotype HA+M+PCO compared with phenotypes HA+PCO and M+PCO. This statistical 144 
difference remained after adjustment for age. Other micro/macro nutrient intake was similar 145 
across phenotype groups.  146 
 147 
Lifestyle 148 
Table 4 shows the comparison of PCOS and control groups based on the domains of lifestyle. 149 
Scores of physical activity, nutrition and weight control in the PCOS group were significantly 150 
lower than in the control group after BMI and age adjustment, indicating a poorer lifestyle in 151 
women in the PCOS group in the mentioned domains above. 152 
 153 
Table 5 shows the lifestyle scores across the different PCOS phenotype groups of women. Scores 154 
of physical activity, nutrition and weight control and psychological health were significantly 155 
lower in HA+M+PCO phenotype after BMI and age adjustment compared with other phenotypes 156 
(P<0.001) indicating a poorer lifestyle of HA+M+PCO phenotype. 157 
 158 
Discussion 159 
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The results of the present study showed that after BMI and age adjustment, energy, fat, saturated 160 
fatty acids and polyunsaturated fatty acids intake were significantly greater in the PCOS group 161 
compared with the control group. Given that quality of the diet increases by fibre and 162 
micronutrients intake, and decreases by saturated fat intake (23), the quality of diet may be lower 163 
in the PCOS group compared with the control group. Our findings suggest that the quality of diet 164 
is positively affected by polyunsaturated fatty acids intake. Previous studies show that quality of 165 
diet is a dietary intake measure which is associated with unfavourable metabolic outcomes and 166 
increased risk of chronic disease mortalities (24, 25). Wild et al. (26) reported increased fat intake 167 
and decreased fibre intake in women with PCOS compared with a control group. Moran et al. (27) 168 
showed women with PCOS had a better diet quality as indicated by a higher diet quality score 169 
and higher energy, fibre, folate, iron, calcium, magnesium, niacin, phosphorus, potassium, 170 
sodium, vitamin E and zinc intake and lower percentage energy from saturated fat intake, 171 
glycaemic index and retinol intake than women without PCOS. It should be noted that in this 172 
study, diagnosis of PCOS was self-reported and dietary intake was measured using a dietary 173 
questionnaire for epidemiological studies. These questionnaires measure 80 types of nutrients 174 
consumed during the past 12 months which differs from the present study as the FFQ is an 175 
appropriate tool for measurement of diet components in a certain period. However, data accuracy 176 
may be limited due to the ability of the responders to remember their intake. Moreover, women 177 
with PCOS reported higher carbohydrate (229 vs. 61 g), protein (78 vs. 66.3 g), fat (85 vs. 61.1 178 
g), saturated fat (26 vs. 22.5 g) intake compared with reference population (28). A high energy 179 
diet has been reported in Iranian (29) and Brazilian (16) women with PCOS. Using three 24-hour 180 
dietary recall questionnaires, Ahmadi et al. (29) reported that daily energy intake (about 300 kcal) 181 
was higher in women with PCOS. These women also had more total and saturated fat intake 182 
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compared with control group (29). A 24 hours dietary diary has similar limitations to the FFQ as it 183 
also depends on an individual respondent’s memory. However, it is an appropriate method which 184 
can present accurate information when it is used by a trained interviewer in a standard approach. 185 
Furthermore, the results of the present study show for the first time that the energy and saturated 186 
fat intake were greater in HA+M+PCO phenotype after age and BMI adjustment compared with 187 
other phenotypes. To date, this is the only study to compare dietary intake PCOS phenotypes 188 
with healthy women. The results of Graff et al. (16) using a 121 items FFQ showed that energy 189 
intake was greater in classic phenotype of PCOS (HA+M+PCO) compared with the control 190 
group; however, this statistical difference did not exist after age and BMI adjustment. It should 191 
be noted that Graff et al considered only two phenotypes of HA+PCO+M (n=39) and ovulatory 192 
PCOS (n=22). In the present study, classification of PCOS phenotype was based on the 193 
Rotterdam criteria.  194 
 195 
It has been shown that HA+M+PCO phenotype has three times higher levels of androgen which 196 
in turns increases the prevalence of glucose tolerance disorder and insulin resistance more than 197 
other phenotypes (16). Testosterone stimulates appetite and an increased level of androgen in 198 
women is associated with appetite control disorder (30). Moreover, hyperandrogenism is essential 199 
in determining the risk of cardiovascular disease in PCOS phenotypes (31). Current clinical 200 
evidence suggests that testosterone increases abdominal fat accumulation (32-34). Increased 201 
abdominal adiposity is associated with increased Leptin hormone and Leptin resistance which 202 
may be associated with increased energy intake (35). High fat intake (total and saturated fat) in the 203 
present study is a concern for patients with PCOS specially HA+PCO+M phenotype; because 204 
fatty acid intake affects the glucose metabolism by making changes in insulin signaling and cell 205 
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membrane function. In addition, high saturation fat diet is associated with decrease insulin 206 
resistance (36). 207 
 208 
However, a high level of physical activity improves the glucose metabolism and sensitivity to 209 
insulin, and reduced abdominal obesity (22); the risk of which is higher in phenotypes 210 
HA+PCO+M. Our results showed for the first time that phenotype HA+M+PCO has less 211 
physical activity compared with two other phenotypes. Wright et al. (37) have reported no 212 
significant difference in self-reported physical activity between American PCOS and non PCOS 213 
patients. This finding is similar to the study of Ahmadi et al. (29), Álvarez-Blasco et al. (38) in 214 
which there was no significant difference in physical activity between PCOS and non PCOS 215 
patients in Iran and Spain. However, it should be noted that similar tools are not used in these 216 
studies to measure physical activity. Wright et al. (37) have used Paffenburg physical activity 217 
questionnaire that is validated in male and female samples. Álvarez-Blasco et al. (38) and Ahmadi 218 
et al. (29) have used interview questionnaires which their validity is uncertain. In the present 219 
study, we have used the Iranian version of the lifestyle questionnaire where the validity and 220 
reliability are approved (30).  221 
 222 
A strength of the present study is that the diagnosis of PCOS phenotypes for allocation to case 223 
study groups was done by an expert physician in the infertility clinic and patients were classified 224 
to the clinical phenotypes based on the Rotterdam criteria. Moreover, a validated FFQ was used 225 
for diet evaluation which is a standard tool for measurement of long term dietary habits in cross 226 
sectional and cohort studies. Lifestyle questionnaire was used to evaluate participants’ lifestyle. 227 
Nevertheless, there are some limitations in the present study. Patients were selected from the 228 
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only referral infertility clinic of Hormozgan province which limits generalization of the study 229 
results. Furthermore, the association between metabolic and hormonal features of the study 230 
population and dietary intake was not included in this study; future studies should consider  231 
different phenotypes of PCOS. In addition, since diet analysis was limited to the nutrition 232 
database, glycaemic load could not be measured in this study. In the current study, we assess 233 
physical activity by a lifestyle questionnaire that was designed by Likert scale. We did not assess 234 
physical activity using metabolic equivalents (METS). This should be considered in the 235 
interpretation of our findings. 236 
 237 
Conclusions 238 
Reduced energy and fat intake is strongly recommended to Iranian women with PCOS especially 239 
with the HA+M+PCO phenotype. It is critical to closely examine the metabolic and endocrine 240 
status of women with menstrual disorder and hyperandrogenism because the treatment strategies 241 
for energy deficit-related menstrual disturbances differ from that of disturbances attributable to 242 
hyperandrogenaemia. Further investigation is necessary to explore whether different endocrine 243 
etiologies underlay menstrual disorder and hyperandrogenism in different phenotypes of PCOS. 244 
Consultation on improvement of psychological health and the importance of nutrition and weight 245 
control, and appropriate physical activity in these patients especially HA+M+PCO phenotype is 246 
necessary. Future studies on the evaluation of the risk of metabolic side effects, dietary intake 247 
and lifestyle is PCOS phenotypes are recommended. 248 
249 
12 
 
Disclosure statement 250 
The authors report no conflicts of interest. 251 
 252 
Transparency declaration  253 
The lead author affirms that this manuscript is an honest, accurate, and transparent account of the 254 
study being reported. The reporting of this work is compliant with the STROBE checklist. The 255 
lead author affirms that no important aspects of the study have been omitted and that any 256 
discrepancies from the study. 257 
 258 
 259 
13 
 
REFERENCES 
1. Bozdag G, Mumusoglu S, Zengin D, et al. (2016) The prevalence and phenotypic 
features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod 31, 
2841-2855 
2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) 
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic 
ovary syndrome. Fertility and sterility 81, 19-25 
3. Azziz R, Carmina E, Dewailly D, et al. (2006) Positions statement: criteria for defining 
polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess 
Society guideline. J Clin Endocrinol Metab 91, 4237-4245 
4. Azziz R, Sanchez LA, Knochenhauer ES, et al. (2004) Androgen excess in women: 
experience with over 1000 consecutive patients. J Clin Endocrinol Metab 89, 453-462 
5. Pasquali R, Gambineri A, Biscotti D, et al. (2000) Effect of long-term treatment with 
metformin added to hypocaloric diet on body composition, fat distribution, and androgen and 
insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J 
Clin Endocrinol Metab 85, 2767-2774 
6. Pasquali R, Fabbri R, Venturoli S, et al. (1986) Effect of weight loss and antiandrogenic 
therapy on sex hormone blood levels and insulin resistance in obese patients with polycystic 
ovaries. American journal of obstetrics and gynecology 154, 139-144 
7. Kiddy DS, Hamilton-Fairley D, Seppala M, et al. (1989) Diet-induced changes in sex 
hormone binding globulin and free testosterone in women with normal or polycystic ovaries: 
correlation with serum insulin and insulin-like growth factor-I. Clin Endocrinol 31, 757-763 
8. Carmina E, Legro RS, Stamets K, et al. (2003) Difference in body weight between 
American and Italian women with polycystic ovary syndrome: influence of the diet. Hum Reprod 
18, 2289-2293 
9. Douglas CC, Norris LE, Oster RA, et al. (2006) Difference in dietary intake between 
women with polycystic ovary syndrome and healthy controls. Fertil Steril 86, 411-417 
10. Liu S, Manson JE, Stampfer MJ, et al. (2000) A prospective study of whole-grain intake 
and risk of type 2 diabetes mellitus in US women. Am J Public Health 90, 1409-1415 
14 
 
11. Meyer KA, Kushi LH, Jacobs DR, et al. (2000) Carbohydrates, dietary fiber, and incident 
type 2 diabetes in older women. Am J Clin Nutr 71, 921-930 
12. Colditz GA, Manson JE, Stampfer MJ, et al.  (1992) Diet and risk of clinical diabetes in 
women. Am J Clin Nutr 55, 1018-1023 
13. Salmeron J, Manson JE, Stampfer MJ, et al. (1997) Dietary fiber, glycemic load, and risk 
of non-insulin-dependent diabetes mellitus in women. JAMA 277, 472-477 
14. Hu FB, Stampfer MJ, Manson JE, et al. (1997) Dietary fat intake and the risk of coronary 
heart disease in women. N Engl J Med 337, 1491-1499 
15. Pikee S, Shivani S, Jayshree B (2016) Endocrine and metabolic profile of different 
phenotypes of polycystic ovarian syndrome. J Obstet Gynaecol India 66, 560-566 
16. Graff SK, Mario FM, Alves BC, et al. (2013) Dietary glycemic index is associated with 
less favorable anthropometric and metabolic profiles in polycystic ovary syndrome women with 
different phenotypes. Fertil Steril 100, 1081-1088 
17. Ferriman D, Gallwey JD (1961) Clinical assessment of body hair growth in women. J 
Clin Endocrinol Metab 21, 1440-1447 
18. Shyangdan D, Clar C, Ghouri N, et al. (2011) Insulin sensitisers in the treatment of non-
alcoholic fatty liver disease: a systematic review. Health Technol Assess 15, 1-110 
19. Donyavi T, Naieni KH, Nedjat S, et al. (2011) Socioeconomic status and mortality after 
acute myocardial infarction: a study from Iran. Int J Equity Health 10, 1475-9276 
20. Hosseini Esfahani F, Asghari G, Mirmiran P, et al. (2010) Reproducibility and relative 
validity of food group intake in a food frequency questionnaire developed for the Tehran lipid 
and glucose study. J Epidemiol 20, 150-158 
21. Piyathilake CJ, Azrad M, Jhala D, et al. (2006) Mandatory fortification with folic acid in 
the United States is not associated with changes in the degree or the pattern of global DNA 
methylation in cells involved in cervical carcinogenesis. Cancer Biomark 2, 259-266 
22. Lali M, Abedi A, Kajbaf MB (2012) Construction and validation of the lifestyle 
questionnaire (LSQ). Psychol Res 1, 64-80 
23. McNaughton SA, Ball K, Crawford D, et al. (2008) An index of diet and eating patterns 
is a valid measure of diet quality in an Australian population. J Nutr 138, 86-93 
24. McNaughton SA, Dunstan DW, Ball K, et al. (2009) Dietary quality is associated with 
diabetes and cardio-metabolic risk factors. J Nutr 139, 734-742 
15 
 
25. Wirt A, Collins CE (2009) Diet quality--what is it and does it matter? Public Health Nutr 
12, 2473-2492 
26. Wild RA, Painter PC, Coulson PB, et al. (1985) Lipoprotein lipid concentrations and 
cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 61, 946-
951 
27. Moran LJ, Ranasinha S, Zoungas S, et al. (2013) The contribution of diet, physical 
activity and sedentary behaviour to body mass index in women with and without polycystic 
ovary syndrome. Hum Reprod 28, 2276-2283 
28. Barr S, Hart K, Reeves S, et al. (2011) Habitual dietary intake, eating pattern and 
physical activity of women with polycystic ovary syndrome. Eur J Clin Nutr 65, 1126-1132 
29. Ahmadi A, Akbarzadeh M, Mohammadi F, et al. (2013) Anthropometric characteristics 
and dietary pattern of women with polycystic ovary syndrome. Indian J Endocrinol Metab 17, 
672-676 
30. Asarian L, Geary N (2006) Modulation of appetite by gonadal steroid hormones. Philos 
Trans R Soc Lond B Biol Sci 361, 1251-1263 
31. Azziz R, Carmina E, Dewailly D, et al. (2009) The Androgen Excess and PCOS Society 
criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 91, 456-
488 
32. Kirchengast S, Huber J (2001) Body composition characteristics and body fat distribution 
in lean women with polycystic ovary syndrome. Hum Reprod 16, 1255-1260 
33. Eisner JR, Dumesic DA, Kemnitz JW, et al. (2003) Increased adiposity in female rhesus 
monkeys exposed to androgen excess during early gestation. Obes Res 11, 279-286 
34. Nohara K, Laque A, Allard C, et al. (2014) Central mechanisms of adiposity in adult 
female mice with androgen excess. Obesity 22, 1477-1484 
35. Galic S, Oakhill JS, Steinberg GR (2010) Adipose tissue as an endocrine organ. Mol Cell 
Endocrinol 316, 129-139 
36. Galgani JE, Uauy RD, Aguirre CA, et al. (2008) Effect of the dietary fat quality on 
insulin sensitivity. Br J Nutr 100, 471-479 
37. Wright CE, Zborowski JV, Talbott EO, et al. (2004) Dietary intake, physical activity, and 
obesity in women with polycystic ovary syndrome. Int J Obes Relat Metab Disord 28, 1026-
1032 
16 
 
38. Alvarez-Blasco F, Luque-Ramirez M, Escobar-Morreale HF (2011) Diet composition and 
physical activity in overweight and obese premenopausal women with or without polycystic 
ovary syndrome. Gynecol Endocrinol 27, 978-981 
 
 
17 
 
Table 1.  Demographic and clinical characterizes of participants 
§ between PCOS and control group 
*ANOVA test 
**Kruskal wallis test 
£ P<0.05 between H+PCO and H+PCO+M phenotype 
€ P<0.05 between H+PCO and M+PCO phenotype 
¥ P<0.05 between H+PCO+M and M+PCO phenotype  
P value§  Control 
 
Phenotype of  PCOS Variable**  
M+PCO 
(n= 57) 
H+PCO+M 
(n= 66) 
H+PCO 
(n= 53) 
Variable  
0.43 29.85±6.40 29.03±9.31 28.41±3.49 29.30±6.25 Age * 
0.62 10.82±4.31 11.04±4.92 11.63±4.11 12.69±3.05 Education * 
0.52 75.3 ±20.8 78.35±10 76.31±15.41 79.43 ±13.1 Weight * 
0.87 33.32±2.96 35.42±2.34 38.43±7.11 39.80±6.53 BMI* 
<0.001 3.62±0.90 6.83±1.10 6.58±2.30 6.93±1.38 Acne score* 
<0.001 9.40±0.18 11.17±0.01 11.03±0.31 11.30±0.84 Hirsutism score* 
     Average menstrual cycle ** 
 13 (8.1) 4 (7.01) 5 (7.57) 2 (3.77) <21 
 76 (47.5) 30 (52.63) 28 (42.42) 22 (41.50) 21-35 
<0.001 8 (5) 9 (15.78) 18 (27.27) 15 (28.30) 35-60 
 18 (11.3) 9 (15.78) 8 (12.12) 6 (11.32) >199 days 
 44 (27.5) 5 (8.77) 7 (10.60) 8 (15.09) Variable  
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Table 2. Comparison of PCOS patients and control group based on the dietary intake 
 
P value adjusted 
for BMI and age 
P value * Control 
(n= 160) 
PCOS 
(n= 168) 
Variable ** 
<0.001 <0.001 2202.8±49.6 2500.2±78.7 Energy (Kcal/day) 
0.82 0.41 74.25±9.36 76.09±10.79 Protein (g/day) 
<0.001 <0.001 65.38±11.75 89.06±12.42 Fat (g/day) 
<0.001 <0.001 21.16±5.56 35.97±9.24 Saturated fatty acids (g/day) 
<0.001 <0.001 15.81±2.48 27.21±2.48 Polyunsaturated fatty acids (g/day) 
0.32 0.21 24.22±9.40 33.10±8.91 Linoleic acid (g/day) 
0.31 0.45 0.01±0.001 0.03±0.002 EPA (g/day) 
0.09 0.06 1353.93±10.21 2223.05± 31.08 Sodium (mg/day) 
0.25 0.43 26.23±6.37 24.13±2.27 Iron (mg/day) 
0.40 0.51 332.83±26.28 395.98±43.09 Magnesium (mg/day) 
0.41 0.59 7.75±2.55 9.68±3.75 Zinc (mg/day) 
0.43 0.98 9.26±4.91 8.64±3.11 Manganese (mg/day)  
0.52 0.61 3163.40±23.50 4129.04±60.51 Fluoride (μg/day) 
0.31 0.45 0.02±0.01 0.28±0.31 Iodine (μg/day) 
0.15 0.39 1347.72±13.10 2701.59±79.35 Vitamin A(μg/day) 
0.81 0.92 3.11±0.85 3.98±0.67 Vitamin E (mg/day) 
0.41 0.35 1.72±0.22 2.34±0.57 Thiamin B1 (mg/day) 
0.51 0.63 17.84±3.97 23.89±5.78 Niacin B3 (mg/day) 
0.31 0.51 302.89±51.24 410.81±14.33 Folate (μg/day) 
0.31 0.60 622.02±10.13 380.26±54.02 Carbohydrate (g/day) 
0.22 0.43 4034.62±36.03 5292.19±80.37 Potassium (mg/day) 
0.12 0.81 861.700±16.69 1234.81±12.91 Calcium (mg/day) 
0.72 0.53 1075.22±79.80 1800.16±10.80 Phosphorus (mg/day)  
*T test, **Mean±SD 
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Table 3. Dietary intake in different phenotypes of PCOS 
*ANOVA, **Mean±SD 
£ P<0.05 between H+PCO and H+PCO+M phenotype 
€ P<0.05 between H+PCO and M+PCO phenotype 
¥ P<0.05 between H+PCO+M and M+PCO phenotype 
 
 
P value adjusted 
for BMI and age 
P value* Phenotype of  PCOS Variable**  
M+PCO 
(n= 57) 
 
H+PCO+M 
(n= 66) 
H+PCO 
(n= 53) 
<0.001 <0.001£€¥ 2346.80± 4.08 2600.8±51.09 2454.2±82.4 Energy (Kcal/ day)  
0.63 0.41 65.96±68.30 91.69±82.38 85.56 ±81.12 Protein (g/day) 
<0.001 <0.001£€¥ 77.56±49.59 89.81±45.38 119.27±55.46 Fat (g/day) 
<0.001 <0.001£€¥ 21.75±15.79 45.06±10.31 29.80±31.67 Saturated fatty acids (g/day) 
<0.001 <0.001£€¥ 25.11±15.25 25.34±13.13 41.54±12.97 Polyunsaturated fatty acids (g/day) 
0.35 0.52 23.59±14.59 45.90±16.17 39.40±12.46 Linoleic acid (g/day) 
0.06 0.09 0.007±0.01 0.05±0.01 0.01±0.01 EPA (g/day) 
0.58 0.31 2907.27±34.58 2523±38.12 1993.41±15.71 Sodium (mg/day) 
0.41 0.38 21.27±24.82 28.46±34.87 21.94±17.26 Iron (mg/day) 
0.96 0.83 362.05±37.70 450.84±64.62 431.99±51.47 Magnesium (mg/day) 
0.82 0.61 9.08 ±0 .76 12.79±2.96 9.74±7.66 Zinc (mg/day) 
0.35 0.21 7.17±.20 10.69±0.12 7.74±4.03 Manganese (mg/day)  
0.41 0.63 7064.76±84.99 5030.95±39.90 6454.85±47.21 Fluoride (μg/day) 
0.51 0.52 .08±.01 0.38±0.12 0.2±.01 Iodine (μg/day) 
0.41 0.35 2473.02±52.84 3512.09±12.02 1962.76± 
16.38 
Vitamin A (μg/day) 
0.51 0.31 3.44±0.42 4.19±0.66 4.30±0.36 Vitamin E (mg/day) 
0.62 0.83 1.82±0.34 2.78±0.70 2.35±0.40 Thiamin B1 (mg/day) 
0.91 0.34 18.95±0.16 30.58±0.91 21.09±0.18 Niacin B3 (mg/day) 
0.72 0.48 377.16±25.36 591.36±64.42 557±74.20 Folate (μg/day) 
0.51 0.64 345.17±39.45 435.06±63.39 433.41±57.31 Carbohydrate (g/day) 
0.43 0.76 4292.63±34.42 6128.09±10.01 5353.94±53.53 Potassium (mg/day) 
0.95 0.62 1089.47±79.86 1238.75±11.09 1386.78±18.24 Calcium (mg/day) 
0.81 0.52 1089.46±79.86 1238.75±11.09 1824.75±16.02 Phosphorus (mg/day)  
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Table 4. Comparison of PCOS and control groups based on the domains of lifestyle 
*T test, **Mean±SD 
  
P value adjusted 
for BMI and age 
P value * Control 
(n= 160) 
PCOS 
(n= 168) 
Variable ** 
0.62 0.38 16.66±3.01 16.32±3.62 Physical health 
0.04 <0.001 15.42±4.82 12.05±3.52 Exercise and fitness 
0.03 <0.001 16.54±3.98 12.49±4.02 Weight control and  nutrition 
0.59 0.45 16.23±4.49 15.82±3.38 Illness prevention 
0.01 <0.001 16.34±3.36 12.90±4.22 Psychological health 
0.71 0.69 18.02±4.28 17.62±3.45 Spiritual health 
0.73 0.53 17.38±5.01 17.56±4.62 Social health 
0.59 0.42 15.95±3.41 16.31±3.42 Drug and alcohol avoidance 
0.48 0.36 17.56±3.51 17.43±3.42 Accident prevention 
0.80 0.74 17.42±4.32 17.36±2.49 Environmental health 
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Table 5. The scores of lifestyles in different phenotypes of PCOS 
 
*ANOVA, **Mean±SD 
£ P<0.05 between H+PCO and H+PCO+M phenotype 
€ P<0.05 between H+PCO and M+PCO phenotype 
¥ P<0.05 between H+PCO+M and M+PCO phenotype 
 
 
 
 
 
 
 
P value adjusted 
for BMI and age 
P value* Phenotype of  PCOS Variable  
M+PCO 
(n= 57) 
 
H+PCO+M 
(n= 66) 
H+PCO 
(n= 53) 
0.55 0.65 16.45±3.08 16.56±3.53 16.02±3.44 Physical health 
<0.001 <0.001£€¥ 13.40±3.29 11.02±2.34 12.34±3.34 Exercise and fitness 
<0.001 <0.001£€¥ 13.39±3.86 10.42±2.35 11.93±2.43 Weight control and  
nutrition 
0.31 0.45 15.42±4.42 14.93±4.24 15.04±3.22 Illness prevention 
<0.001 <0.001£€¥ 13.20±3.82 10.56±2.94 12.42±1.32 Psychological health 
0.25 0.33 17.83±5.01 16.92±6.42 17.53±7.34 Spiritual health 
0.35 0.45 17.45±5.92 17.24±3.56 17.32±6.45 Social health 
0.42 0.56 16.93±4.32 16.02±4.41 16.42±5.62 Drug and alcohol avoidance 
0.65 0.71 17.21±4.35 16.92±2.39 17.05±3.56 Accident prevention 
0.83 0.93 17.28±4.62 17.25±1.95 17.32±4.23 Environmental health 
